Rubius Therapeutics, Inc. (RUBY) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Cambridge, MA, 美国. 现任CEO为 Laurence A. Turka.
RUBY 拥有 IPO日期为 2018-07-18, 6 名全职员工, 在 NASDAQ Global Select.
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
